The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

@article{Labonte2011TheDE,
  title={The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.},
  author={Melissa Janae Labonte and Peter Murray Wilson and Will Fazzone and Jared R Russell and Stan Gee Louie and Anthony B El-Khoueiry and H. P. Lenz and Robert D. Ladner},
  journal={Cancer research},
  year={2011},
  volume={71 10},
  pages={3635-48}
}
As key molecules that drive progression and chemoresistance in gastrointestinal cancers, epidermal growth factor receptor (EGFR) and HER2 have become efficacious drug targets in this setting. Lapatinib is an EGFR/HER2 kinase inhibitor suppressing signaling through the RAS/RAF/MEK (MAP/ERK kinase)/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/AKT pathways. Histone deacetylase inhibitors (HDACi) are a novel class of agents that induce cell cycle arrest and apoptosis… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Colorectal cancer: epigenetic alterations and their clinical implications.

Biochimica et biophysica acta. Reviews on cancer • 2017
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 49 references

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2007
View 10 Excerpts
Highly Influenced

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2010
View 1 Excerpt

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…